Cargando…
STAT3 Inhibitor OPB-51602 Is Cytotoxic to Tumor Cells Through Inhibition of Complex I and ROS Induction
STAT3 is a transcription factor involved in several cellular activities including inflammation, proliferation, and survival, but it also plays a non-transcriptional role in modulating mitochondrial metabolism. Given its diverse functions in human cancers, it is an emerging therapeutic target. Here w...
Autores principales: | Brambilla, Lara, Lahiri, Tanaya, Cammer, Michael, Levy, David E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708861/ https://www.ncbi.nlm.nih.gov/pubmed/33305182 http://dx.doi.org/10.1016/j.isci.2020.101822 |
Ejemplares similares
-
Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
por: Ogura, Michinori, et al.
Publicado: (2015) -
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
por: Oh, Do-Youn, et al.
Publicado: (2015) -
Mitochondrial STAT3 regulates antioxidant gene expression through complex I‐derived NAD in triple negative breast cancer
por: Lahiri, Tanaya, et al.
Publicado: (2021) -
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
por: Hayakawa, F, et al.
Publicado: (2013) -
Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
por: Yoo, Changhoon, et al.
Publicado: (2019)